Barclays raised the firm’s price target on Teva to $20 from $17 and keeps an Overweight rating on the shares post the Q1 report. The analyst says Teva’s turnaround continues with compelling growth across Austedo, Ajovy and generics. The firm believes the company is in the “early innings of a long growth phase.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Options Volatility and Implied Earnings Moves Today, May 08, 2024
- Options Volatility and Implied Earnings Moves This Week, May 06 – May 10, 2024
- Teva Pharmaceutical Industries Limited (TEVA) Q1 Earnings Cheat Sheet
- Teva call volume above normal and directionally bullish
- FTC expands patent listing challenges for drugs